— Know what they know.
Not Investment Advice

ALMR NASDAQ

Alamar Biosciences, Inc.
1W: +4.8% 1M: +12.7% 3M: +33.9% YTD: +56.2%
$34.36
+1.90 (+5.85%)
 
Weekly Expected Move ±9.2%
$28 $31 $34 $38 $41
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 67 · $2.4B mcap · 36M float · 0.997% daily turnover · Short 73% of daily vol
Smart Money Score
Moderate 50
Insider+$8.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.4B
52W Range18.85-38.54
Volume339,899
Avg Volume359,858
Beta-6.18
Dividend—
Analyst Ratings
2 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOYuling Luo
Employees222
SectorHealthcare
IndustryBiotechnology
IPO Date2026-04-17
47071 Bayside Parkway
Fremont, CA 94538
US
(510) 626-9888
About Alamar Biosciences, Inc.

Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.

Recent Insider Trades

NameTypeSharesPriceDate
Brottem John L. A-Award 29,000 — 2026-09-14
Brottem John L. A-Award 85,000 $27.99 2026-09-14
Brottem John L. 0 — 2026-09-14
RAGUSA ROBERT P 0 — 2026-09-01
RAGUSA ROBERT P A-Award 5,686 — 2026-09-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms